Leslie Eiland, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1366678922
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,010 of the $17,496 with a category attached, or 97.2%. 11 manufacturers reported payments, led by Eli Lilly at 37.3% of the total. Among endocrinology, diabetes & metabolism clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $1249.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7K
- Roche Diabetes Care, Inc.$3K
- Roche Diagnostics Corporation$3K
- Novo Nordisk$3K
- Sanofi-aventis U.S. LLC$2K
- Dexcom, Inc.$297
- plus $189 from 5 others
What the payments were for
- Consulting fees$17,01097%
- Food & beverage$4272%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $6,525 |
| Roche Diabetes Care, Inc. | 1 | $2,900 |
| Roche Diagnostics Corporation | 1 | $2,870 |
| Novo Nordisk | 2 | $2,790 |
| Sanofi-aventis U.S. LLC | 1 | $1,925 |
| Dexcom, Inc. | 2 | $297 |
| Mannkind Corporation | 1 | $59 |
| Genentech, Inc. | 1 | $55 |
| Lilly USA, LLC | 1 | $31 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,496 in reported general payments places this provider in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $62,077 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $41,840 |
| MounjaroTirzepatide | 19 | $24,858 |
| TrulicityDulaglutide | 20 | $22,874 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $22,290 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $16,222 |
| Novolog FlexpenInsulin Aspart | 25 | $9,371 |
| HumalogInsulin Lispro | 17 | $8,630 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $8,158 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $7,365 |
| NovologInsulin Aspart | 19 | $6,286 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $2,434 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 17 | $2,237 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,416 |
| Levothyroxine Sodium | 78 | $1,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $2,790 | $68,36268 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $31 | $56,36256 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
- Mohsen ZenaOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.